Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Essential hypertensive patients
Moderate to severe Patients with uncontrolled blood pressure (systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg for untreated, systolic blood pressure ≥150mmHg, diastolic blood pressure ≥95mmHg for treated on monotherapy).
Patients are willing to discontinue previous antihypertensive medicine
You may not be if
Pregnant or lactating women, or women of child bearing potential without contraceptive method.
Hypersensitivity to any component of the products or other sulfonamide derived substances.
Secondary hypertension.
Severe renal impairment (Creatinine Clearance ≤30ml/min)
Severe hepatic impairment, biliary cirrhosis and cholestasis.
Refractory hypokalemia, hypercalcaemia.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
